Drug Profile
Research programme: atherosclerosis and metabolic disorder therapies - AtheroNova
Alternative Names: AHRO-003; AHRO-010; AHRO-100; AHRO-200; AHRO-300; HDCA - AtheroNova; Hyodeoxycholic acid - AtheroNovaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AtheroNova
- Class Bile acids and salts; Terpenes
- Mechanism of Action Cholesterol absorption inhibitors; Gene expression stimulants; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Lipid metabolism disorders; Obesity; Stroke
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA